Skip to content

Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease

Association of Light-to-moderate Alcohol Consumption With Risk of Type 2 Diabetes Mellitus in Individuals With Nonalcoholic Fatty Liver Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03847116
Enrollment
14014
Registered
2019-02-20
Start date
2009-01-01
Completion date
2019-02-10
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Light-to-moderate Alcohol Consumption, Nonalcoholic Fatty Liver Disease, Type2 Diabetes Mellitus

Brief summary

This study explored the cross-sectional and prospective associations between light-to-moderate alcohol consumption (LMAC) and risk of type 2 diabetes mellitus (T2DM) in individuals with nonalcoholic fatty liver disease (NAFLD).

Interventions

None listed

Sponsors

Ningbo No. 1 Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. aged 18 years or above 2. undergoing annual health examinations in 2009 in Zhenhai Lianhua Hospital, Ningbo, China. 3. informed about the study

Exclusion criteria

1. female participants; 2. missing data on ultrasound, alcohol consumption, and T2DM status; 3. alcohol consumption \> 210 g per week, and binge drinkers; 4. with evidence of other liver diseases including viral hepatitis, autoimmune hepatitis, and drug-induced liver disease.

Design outcomes

Primary

MeasureTime frameDescription
Light-to-moderate alcohol consumption (LMAC) and risk of prevalent type 2 diabetes mellitus (T2DM)cross-sectional analyses in 2009Fatty liver was assessed by ultrasound. T2DM was defined as the presence of any of the following conditions based on American Diabetes Association criteria: (1) fasting plasma glucose (FPG) ≥ 7.0 mmol/L; (2) hemoglobin A1c (HbA1c) ≥ 6.5%; (3) self-reported clinician-diagnosed T2DM.

Secondary

MeasureTime frameDescription
LMAC and incident risk of T2DM9-year cohort observationFatty liver was assessed by ultrasound. T2DM was defined as the presence of any of the following conditions based on American Diabetes Association criteria: (1) fasting plasma glucose (FPG) ≥ 7.0 mmol/L; (2) hemoglobin A1c (HbA1c) ≥ 6.5%; (3) self-reported clinician-diagnosed T2DM.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026